{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-023440","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.537362+00:00","generated_at":"2026-05-15T21:49:02.782863+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Citius Oncology reports positive Phase 1 data for LYMPHIR prior to CAR-T in DLBCL","bullets":["Overall response rate 86% (57% complete response, 29% partial response) at one month in 14 patients.","One-year progression-free survival 77% (95% CI 43-92%); overall survival 84% (95% CI 49-96%).","LYMPHIR well-tolerated with no dose-limiting toxicities; no Grade ≥3 LYMPHIR-related immune AEs.","Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL); supports larger trial.","Study enrolled high-risk relapsed/refractory DLBCL patients; all proceeded to CAR-T infusion."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-023440","json":"https://secwatch.observer/filing/0001213900-26-023440.json","markdown":"https://secwatch.observer/filing/0001213900-26-023440.md","text":"https://secwatch.observer/filing/0001213900-26-023440.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/0001213900-26-023440-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:49:02.782863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}